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Abstract
Background: Neutralizing antibody assessments play a central role in human immunodeficiency virus type-1 (HIV-1) vaccine
development but it is unclear which assay, or combination of assays, will provide reliable measures of correlates of
protection. To address this, an international collaboration (NeutNet) involving 18 independent participants was organized to
compare different assays.
Methods: Each laboratory evaluated four neutralizing reagents (TriMab, 447-52D, 4E10, sCD4) at a given range of
concentrations against a panel of 11 viruses representing a wide range of genetic subtypes and phenotypes. A total of 16
different assays were compared. The assays utilized either uncloned virus produced in peripheral blood mononuclear cells
(PBMCs) (virus infectivity assays, VI assays), or their Env-pseudotyped (gp160) derivatives produced in 293T cells (PSV assays)
from molecular clones or uncloned virus. Target cells included PBMC and genetically-engineered cell lines in either a single-
or multiple-cycle infection format. Infection was quantified by using a range of assay read-outs that included extracellular or
intracellular p24 antigen detection, RNA quantification and luciferase and beta-galactosidase reporter gene expression.
Findings: PSV assays were generally more sensitive than VI assays, but there were important differences according to the
virus and inhibitor used. For example, for TriMab, the mean IC50 was always lower in PSV than in VI assays. However, with
4E10 or sCD4 some viruses were neutralized with a lower IC50 in VI assays than in the PSV assays. Inter-laboratory
concordance was slightly better for PSV than for VI assays with some viruses, but for other viruses agreement between
laboratories was limited and depended on both the virus and the neutralizing reagent.
Conclusions: The NeutNet project demonstrated clear differences in assay sensitivity that were dependent on both the
neutralizing reagent and the virus. No single assay was capable of detecting the entire spectrum of neutralizing activities.
Since it is not known which in vitro assay correlates with in vivo protection, a range of neutralization assays is recommended
for vaccine evaluation.
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Introduction
It is well established that neutralizing antibodies play a pivotal
role in mediating protection against a range of virus infections
including polio, measles, hepatitis and influenza [1] and it is a long
held and widespread belief that they probably contribute to
protection from human immunodeficiency virus type-1 (HIV-1)
infection and/or disease [2]. Evidence in favor of a beneficial
effect of HIV-1 neutralizing antibodies has been presented over
the years [3,4,5,6,7,8]. Despite this, early moves towards vaccine
clinical studies in the early 1990s were discouraged by the limited
titer and very narrow specificity of neutralizing antibodies induced
by natural infection or immunization if neutralization was detected
at all [9,10,11,12]. Furthermore, the high level of genetic
variability of the virus and its escape from the neutralizing
antibody response are well documented and have further
discouraged the HIV-1 vaccine field from considering the
induction of humoral immunity as a pre-requisite for an effective
HIV-1 vaccine [13,14]. Consequently, in the late 1990s and the
early years of this century vaccine efforts were mainly focused on
eliciting a cellular immune response but, unfortunately, these have
also failed to provide effective protection against HIV-1 [15,16].
Over the years a wide range of HIV-1 neutralization assays and
variants thereof have been developed and described in the
literature. It became apparent by the early 1990s that HIV-1
neutralization assays and reagents should be compared and
evaluated and this was best done by international networks
[17,18]. Analogously the World Health Organization (WHO)
Network for HIV Isolation and Characterization undertook
detailed genetic, biological and immunological characterization
of globally prevalent and epidemiologically important HIV-1
isolates. These and other studies from several other laboratories
led to the conclusion that antigenic variability may not present
such an insurmountable obstacle to vaccine development, and
since broadly cross-neutralizing antibodies can be detected in
some HIV-1-infected individuals, these should be sought for in the
context of HIV-1 vaccine development [19,20,21]. A WHO/
UNAIDS consultation on regulation and clinical evaluation of
HIV/AIDS preventive vaccines held in March 2001 recommend-
ed that a consensus be sought on methods to assess serological and
cellular immune responses. This resulted in a WHO/UNAIDS
workshop being convened on ‘Progress in the development and
standardization of methods to measure HIV-1 neutralizing
antibodies in HIV vaccine research and clinical trials’ at the San
Raffaele Scientific Institute in Milan, Italy, in 2003, and was
attended by 18 participants from 12 different countries from
Europe, Africa, Asia and the Americas. The primary achievements
of this meeting were to prepare recommendations on priorities for
the standardization and quality control of HIV-1 neutralization
assays and to organize an international multi-laboratory collabo-
rative study to compare neutralization methods using a selected
panel of international HIV-1 isolates and serologic reagents.
Subsequently in 2004, a group of 11 laboratories, performing a
range of different techniques to measure neutralizing antibodies,
proceeded with the co-ordination of an international collaborative
study, called NeutNet, aimed at the standardization of HIV-1
neutralization assays to be used in vaccine research and clinical
trials. The group has been extended over the years to 15
laboratories and has completed the first phase of the study using
different monoclonal antibodies (Mabs) and soluble (s)CD4 tested
against 11 HIV-1 isolates and their clonal derivatives in 16
different assays.
As described in a recent minireview [22], efforts to characterize
HIV-1 neutralization assays and reagents have been carried out by
other consortia such as the studies initiated by the Laboratory
Standardization Subcommittee for the Global HIV AIDS Vaccine
Enterprise (GHAVE).Data wereobtained essentiallyfromtwo HIV-
1 neutralization assays, one using primary HIV-1 isolates and
peripheral blood mononuclear cells (PBMC assay) for infection and
the other using pseudoviruses derived from corresponding isolates
and the TZM-bl reporter cell line. The results showed that the
degree of correlation between the two assays was dependent on the
reagents used for neutralization. The NeutNet study, comparing a
broader range of neutralization assays, has reached at a similar
conclusion. A summary of these studies was presented at the global
workshop on Standardization of HIV Neutralization Assays for Use
in Vaccine Research and Clinical Trials, held at Varese, Italy, on
March 17–18, 2007 [23]. The present article describes the results of
the first phase of the NeutNet study and provides recommendations
for the use of a range of neutralization assays including pseudovirus/
recombinant virus, HIV-1 isolates, primary cells (PBMC, and
macrophages) and cell lines, as well as new approaches to evaluate
inhibitory antibodies (such as plaque reduction, cell-to-cell fusion
assays, and complement inhibition assays).
Methods
Neutralization Assays
The methodologies used in this study are listed in Table 1 and
differences between assay protocols in supplementary Table S1
and supplementary Figure S1. Detailed protocols are available at
the EUROPRISE website www.europrise.org. The conventional
PBMC based assay [24,25,26,27] with readout based on p24
antigen production involves multiple rounds of virus replication,
has a moderate reproducibility and sensitivity, is time-consuming
and cumbersome to perform but involves the most physiological
target cell. An alternative readout can be the measurement of viral
RNA, which shortens the time by several days [28,29].
Intracellular (IC) p24 antigen determination in infected PBMC
cultures may be run as a single round assay with increased
sensitivity, reproducibility and speed but it is not easy to perform
[30]. The method of measuring ICp24 was also applied to other
target cells, like macrophages [31]. Plaque reduction assays use
either U87.CD4 or GHOST(3) cells engineered to express
coreceptors for HIV [32,33]. In U87.CD4 cells the syncytium-
inducing capacity of HIV is exploited, while infected GHOST(3)
cells turn green due to the activation of the GFP gene linked to the
HIV-2 LTR. These assays are single round, highly reproducible,
easy to perform, with sensitivity comparable to the PBMC assay,
but require a shorter time. The fusion assay is based on fusion of
effector cells expressing the native HIV-1 envelope on their surface
(PM1 persistently infected with HIV-1) with target cells expressing
the appropriate receptors (initially NIH-3T3 mouse fibroblasts or
HeLa human epithelial cells stably expressing human CD4, CCR5
and/or CXCR4). The readout is measurement of ß-galactosidase
activity [34]. Pseudovirus (PSV)-based assays exist in a number of
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selected molecular clone is tested in a single round assay with
luciferase readout that results in short-term assays with high
reproducibility and sensitivity. Plasmid production and producer
cell line culture history are crucial criteria and influences the
results. Due to this a fairly large inter-laboratory variation has
been documented [23]. Finally, assays using recombinant viruses
have also been included [39,40,41]. This assay type was run with
two different starting materials, env sequences were amplified either
from culture supernatants or from cloned plasmid.
Inhibitory reagents
Mabs and soluble sCD4 were distributed by the Programme
EVA Centre for AIDS Reagents (CFAR) NIBSC, UK. Mabs 2F5,
2G12 and 4E10 were kindly provided by Dr. D Katinger,
Polymun Scientific GmbH, Austria, b12 by Dr D Burton, The
Scripps Research Institute, USA and 447-52D by Dr S Zolla-
Pazner, New York University Medical Center, USA. The sCD4
was purchased from Progenics Pharmaceuticals Inc, USA. Three
monoclonal antibody reagents were tested including TriMab, an
equal mixture of the three Mabs IgG1b12, 2G12 and 2F5; Mabs
447-52D and 4E10. The Mabs and sCD4 were tested at starting
concentrations of 25 mg/ml and 10 mg/ml, respectively, followed
by five 2-fold dilutions. Mab IgG1b12 is directed to the CD4-
binding domain of HIV-1 envelope gp120 [42], 2G12 is directed
to a 1R2mannose residues of gp120 [43], while 2F5 and 4E10 are
specific for the transmembrane-proximal region of gp41 [44,46].
Antibody 447-52D is specific for the third variable loop (V3) of
gp120 [45]. The integrity of the Mabs was confirmed by PAGE
gels and their HPLC profile established (data not shown).
Viruses
Twelve HIV-1 isolates and/or their clonal derivatives were used
(see Figure 1 for listing). The viruses chosen represented different
HIV-1 subtypes, varying neutralization sensitivity and coreceptor
usage and included several presently used as vaccine strains. Three
of the subtype B viruses, B (US), are from a virus panel currently in
use for evaluating vaccine candidates [47]. Viruses were prepared
and supplied to each participant by CFAR thereby ensuring that
all the laboratories had a common starting material. Each
participant laboratory subsequently expanded the stock/plasmid
as needed and titered for use. NP1525 was available only as virus
supernatant and CAAN5342 was only available as a clonal
derivative. Each laboratory received a panel of 11 different viruses
for testing. Virus isolates 92RW009, 92BR025 and 92UG024
originated from the WHO/UNAIDS HIV Network and were
provided to CFAR by the NIH AIDS Research and Reference
Reagent Program (ARRRP).
Statistical analysis
Analysis was based on the raw assay data returned by
participating laboratories. Each laboratory was requested to
perform twice the assays according to their standard protocol,
with all dilutions tested at least in duplicates. The 50%, 75% and
90% inhibitory concentrations (IC50, IC75 and IC90) were
calculated with a linear interpolation method, using the mean of
the duplicate responses.
The linear interpolation method was implemented in an Excel
spreadsheet, allowing consistent calculation of the IC50 values that
was across laboratories. The assay readout equivalent to the IC50
was calculated as half the assay readout with no antibody present
Table 1. Neutralization assays and their characteristics.
Assay Cell target Infection
Ab
persistence
3 Read-out assay Day
4 Virus type Lab
7
Virus Infectivity
Assay
Extra cellular p24 PBMC MR 24 hr ELISA 7 Isolate 3B, 5A
constant 7, 10 7
24 hr 14 6B
Intra cellular p24 SR constant Flow Cytometry 2 High Titer Isolate 8
Viral RNA MR constant Real Time PCR 4 Isolate 11
Plaque formation Ghost/U87
1 SR 24 hr Microscopy: Green (Ghost) or
Syncytial (U87) cells
3 Isolate 9
Fusion 3T3.T4. CCR5/CXCR4 SR
2 constant b-Galactosidase 2 hr Isolate 3A
Pseudotyped
Virus Based
Assay
Pseudotyped Virus U87
1 SR constant Luciferase 3 Env plasmid
5 13, 4B
TZMbl 22 , 5 B , 1 0
3T3.T4. CCR5/CXCR4 2 1
Ghost 36 A
Recombinant Virus U87
1 SR constant Luciferase 3 Isolate
6 4A
U87
1 MR 5 12
MR=multiple round, SR=single round.
1cells are stably transfected with CD4 and CCR5 or CXCR4.
2Limited to cell-surface envelope/receptor interaction.
3Time of incubation of the inhibitor/antibody with the virus and cells before washout.
4Day at which read-out was performed; hr means hours when indicated.
5Env expression plasmids (obtained through NIBSC).
6Env was PCR amplified starting from culture supernatant.
7Laboratory code.
doi:10.1371/journal.pone.0004505.t001
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IC50 was identified, with assay readout for adjacent dilutions
being above and below the 50% readout. The assay readouts for
the dilutions above and below the IC50 were joined with a straight
line, plotted against the log concentration of antibody. The
position where the line crossed the 50% assay readout was taken as
the estimate of IC50. Where the IC value was outside the range of
concentrations tested, it was recorded as either greater than the
highest concentration used, or less than the lowest concentration,
as appropriate. Where the assay data were variable, and the
observed dose-response crossed the relevant percentage inhibition
level (e.g. 50% inhibition for IC50) more than once, no IC value
was calculated. Absence of a calculated IC value may therefore be
due to a laboratory not testing a particular combination of virus
and antibody, or to the resulting assay data being too variable to
allow a calculation. The variable data quality precluded the use of
more sophisticated curve-fitting models for calculation of IC
values.
For each laboratory, a geometric mean IC value for the repeat
tests was calculated. For each virus and antibody combination, an
overall geometric mean of the individual laboratory means was
calculated, along with the minimum, maximum, and range
between laboratories. To allow calculations of the geometric
means, any IC value that was greater than the highest
concentration used were taken as equal to the next two-fold
dilution step, so results recorded as .25 were taken as equal to 50.
Similarly, IC values that were below the lowest concentration were
taken as the next two-fold dilution step. IC values that were below
0.78 are recorded as ,0.78, even if a lower IC value could be
calculated from an extended dilution series. Although this may not
fully reflect the differences in sensitivities of different assays, it does
allow a consistent comparison between different laboratories and
groups of assay methods, without introducing any bias from the
range of concentrations included in the assays.
Results
Calculated Inhibitory Concentration values
The majority of assays had IC90 values above the highest
concentration of inhibitor used. The IC75s were also above the
highest concentration tested for many assays, particularly for 447-
52D and sCD4. The calculated IC50s were used for all subsequent
analyses.
Overall neutralization assay results
The overall pattern of neutralization of the different viruses by
the four reagents is shown in Figure 1, as a color-coded table. The
table values are the geometric mean IC50 (mg/ml) from the
indicated laboratory for a given inhibitor tested with each virus.
The cells range from green representing weak or no neutralization
(IC50.25 mg/ml; .10 mg/ml for sCD4) to red representing
strong neutralization (IC50,1.0 mg/ml). Empty (white) cells
indicate a data point not reported by a participant, or a place
where data points were too variable to allow the calculation of an
IC50 value. The laboratories are grouped according to the type of
assay that they performed, indicated by titles at the top of the
tables.
TriMab, a mixture of three Mabs, was the most effective and
broadly neutralizing of the four reagents used. Given that Mab
447-52D is specific for viruses that carry the GPGR motif at the tip
of the V3 loop [2], a characteristic of most subtype B viruses but of
few non-B viruses, it displayed the most consistent reactivity with
two of four subtype B viruses and VI191 (subtype A with a GPGR
V3 motif), but little activity with viruses of other subtypes.
As illustrated in Figure 1 different viruses showed a differential
sensitivity to neutralization by the various Mabs and sCD4. For
example, SF162 was generally easier to neutralize than other
viruses, showing strong neutralization by 447-52D, but much less
so by 4E10. Moreover, there were significant differences in the
ability of the different assays to detect neutralization. For example,
the fusion assay of laboratory 3A had a strikingly higher sensitivity
threshold than the other assays when testing Mabs, but very
comparable sensitivity when testing sCD4.
Intra-laboratory variation
Figure 2 shows as an example the calculated IC50s from
individual tests performed by laboratories for SF162 with TriMab
and 4E10. Many laboratories only provided results from a single
assay, and a full assessment of intra-laboratory repeatability is not
possible. For laboratories that did return data from repeat assays,
the IC50s were generally within a 2–4 fold range. This is much
lower than the variation between laboratories, even between
laboratories performing nominally the same assay. However, given
the limited nature of the data it is not possible to draw any firm
conclusions.
Inter-laboratory and inter-assay variation
The aim of the present study was to compare the performance
of a wide variety of HIV-1 neutralization assays as performed in
different laboratories (Table 1). The viruses and inhibitory
reagents were provided by a common source and there were
certain standards requested in the assay setup including the
starting of the titrations at 25 mg/ml for the Mabs and 10 mg/ml
for sCD4, with subsequent 2-fold dilution series. Inter-laboratory
comparisons were made on a range of dilutions common to all
laboratories. IC50s below 0.78 are indicated as ,0.78.
Direct comparison of the PSV and VI assays was possible with
10 viruses. The results of the fusion assay were not included in
these calculations. The PSV assays were generally more sensitive
than VI assays, but there were important differences according to
the virus as well as the neutralizing reagent.
Tables 2, 3 and 4 list the overall mean IC50s for neutralization
by TriMab, along with the fold-range (max/min) between
laboratories. Since for many of the laboratories the mean IC50s
were outside the range of concentrations used, the quoted fold-
range is a minimum observed range (for example, a range from 2.5
to .25 is presented as .10-fold; the true range is unknown). For
TriMab, the mean IC50 was lower for PSV than for VI assays in
Figure 1. Mean inhibitory concentration (IC) 50 values for duplicate assays performed with virus and reagent as indicated. Each
column represents the results obtained with one assay. The cells are color coded: green, poor or no neutralization IC50.25 mg/ml (.10 mg/ml for
sCD4); yellow, IC50 5–25 mg/ml (5–10 mg/ml for CD4); orange, IC50 1–5 mg/ml; red, IC50,1 mg/ml. White cells occur where no results are available.
Assays are grouped on the basis of several criteria: 1) the use of plasmids or culture supernatants as a source for HIV-1; 2) fusion based assays or
infection based assays, either with pseudotyped virus or replication competent virus; and 3) the use of cell lines or PBMC. Laboratories performing the
assays are numbered (see Table 1 for reference) and color coded; blue: TZM-bl assays or PSV/plasmid assays; green: PBMC assays using extracellular
p24 as readout; pink: plaque reduction assay. In the listing of viruses to the left, the cells of X4 viruses are labeled grey, the cells of R5 viruses are
white. NP1525 was available only as virus supernatant whereas, CAAN5342 as clonal derivative.
doi:10.1371/journal.pone.0004505.g001
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4E10 or sCD4 suggested greater sensitivity for those reactions of
the VI compared to the PSV assay (e.g., SF162 vs. 4E10 lower, vs.
sCD4 similar; whereas VI191 vs. 4E10 similar and vs. sCD4 lower
IC50s in VI assays than in PSV assays; Figure 1). For TriMab,
with viruses for which a comparison of ranges between
laboratories could be made (QH0692 and AC10), the PSV assays
performed in different laboratories were in better agreement with
each other than the VI assays, whereas for VI191 agreement
between laboratories was equally poor. For CM244 the opposite
was true since the VI assays were in better agreement than the
PSV assays (Table 2). For other viruses, no comparisons could be
made since several laboratories had IC50 values outside the range
of concentrations (,0.78 or .25). This was also true for 4E10 and
sCD4.
When comparing plasmid-based assays with culture superna-
tant-based assays (see Figure 1 for subdivision of assay types) the
overall pattern was similar to the PSV vs. VI assay comparison
(Table 3). Nevertheless, it was possible to compare ranges between
laboratories for more viruses, and the plasmid-based assays were in
better agreement with each other than the culture supernatant-
based assays for VI191 and DU174 as well as for QH0692 and
AC10. The mean IC50s with TriMab were lower in the plasmid-
based assays than in culture supernatant-based assays for all but
one virus (VI191), although the consistency of assays between
laboratories was in favor of the plasmid-based assays (7-fold and
21.7-fold range, respectively, Table 3).
Variation within plasmid based assays
The TZM-bl assay (performed by three laboratories, numbered
2, 5B and 10) was compared to all other plasmid-based assays
(comprising four laboratories, numbered 6A, 1, 4B and 13). The
results largely depended on the virus used (Figure 1 and Table 4).
For TriMab, the TZM-bl assays gave good neutralization for all
viruses, with good agreement between laboratories (fold range 1.2–
2.4; with the exception of 92BR025 .5.6). For the other plasmid
assays, the results depended on the virus, with poor neutralization
for 92RW009, VI191 and CM244. For the other viruses, the
Figure 2. Intra-lab variation of neutralization performed with SF162. Light blue coded laboratory performed TZM-bl assay; green coded
laboratory performed extracellular p24 reduction readout assay and pink coded laboratory performed placque reduction assay. Assays are grouped as
in Figure 1.
doi:10.1371/journal.pone.0004505.g002
Table 2. Inter-Laboratory comparisons with TriMab
a.
Pseudovirus Based Assays (PSV)
c Virus Infection Assays (VI)
d
Virus N lab
b Mean IC50 Min IC50 Max IC50 Fold Range N lab
b Mean IC50 Min IC50 Max IC50 Fold Range
92RW009 7 14.98 2.52 .25 .9.9 7 16.52 5.66 .25 .4.4
VI 191 8 4.13 0.88 15.30 17.5 7 5.22 1.15 19.04 16.6
SF 162 9 ,0.78 ,0.78 ,0.78 - 7 1.33 ,0.78 5.50 .7.1
MN(P) 7 ,0.78 ,0.78 1.00 .1.3 5 2.80 ,0.78 11.22 .14.4
QH0692 8 1.37 0.80 2.61 3.3 7 5.23 ,0.78 10.86 .13.9
AC10 8 4.14 2.96 8.70 2.9 6 11.19 2.99 21.27 7.1
DU174 8 1.66 ,0.78 4.80 .6.2 7 10.19 2.03 .25 .12.3
92BR025 8 2.52 ,0.78 7.00 .9.0 5 10.40 1.97 .25 .12.7
92UG024 7 0.88 ,0.78 3.10 .4.0 6 2.22 ,0.78 12.09 .15.5
CM244 7 7.57 1.94 22.03 11.3 7 23.24 13.22 .25 .1.9
aall values of the ICs are expressed as mg/ml. A dash indicates: not possible to calculate.
bNumber of laboratories performing the assay.
cLaboratories involved: 1, 2, 4A, 4B, 5B, 6A, 10, 12, 13.
dLaboratories involved: 3B, 5A, 6B, 7, 8, 9, 11.
doi:10.1371/journal.pone.0004505.t002
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neutralized all viruses in the TZM-bl assays, but was weak or did
not neutralize 92RW009, VI191 and SF162 in the other plasmid-
based assays. For sCD4, VI191, AC10, CM244 and CAAN5342
showed poor or no neutralization with both sets of assays. For the
other viruses and reagents, the overall neutralization profile was
similar in the two types of assays (Figure 1).
Variation within PBMC based assays
PBMC-based assays with different readouts were compared.
Four laboratories used extracellular p24 (EC-p24) detection
(laboratories 3B, 6B, 7 and 5A), while intracellular p24 (IC-p24)
or RNA viral load by real-time PCR comprised the other group
(laboratories 8 and 11). No general trend between assay types was
evident, since the observed range was affected by the cut-off of 25
(or 10) mg/ml as the highest concentration of reagent tested.
There are several variables in the preparation of PBMC and in
neutralization assay protocols (Table 1 and supplementary Table
S1), which may have an impact on assay sensitivity. According to
their sensitivity to neutralization of SF162 with TriMab or 4E10
(Tables 2, 3 and 4) laboratories could be divided into three
categories. Sensitive, IC50 reached with ,0.78 mg/ml Mab;
resistant, high concentrations needed (TriMab) or highest
concentration not sufficient (4E10) to reach IC50; and moderately
sensitive, with IC50 values in between (sensitive,moderately
sensitive,resistant). Of all the variables, the length of time during
which the antibody was present correlated best with the sensitivity
of the assay. The longer the antibody was present in the culture,
the better the neutralization that was achieved. The three
laboratories (numbered 6B, 7 and 8) that neutralized SF162 to
the highest level had in common the constant presence of antibody
or a 24-hour incubation period with antibody and virus prior to
Table 3. Inter-Laboratory comparisons with TriMab
a.
Culture Supernatant Based Assays
c Plasmid Based Assays
d
Virus N lab
b Mean IC50 Min IC50 Max IC50 Fold Range N lab
b Mean IC50 Min IC50 Max IC50 Fold Range
92RW009 9 17.40 5.66 .25 .4.4 5 13.12 2.52 .25 .9.9
VI 191 9 3.67 0.88 19.04 21.7 6 6.48 2.06 15.30 7.4
SF 162 9 1.10 ,0.78 5.50 .7.1 7 ,0.78 ,0.78 ,0.78 -
MN(P) 7 1.82 ,0.78 11.22 .14.4 5 ,0.78 ,0.78 1.00 .1.3
QH0692 9 3.86 ,0.78 10.86 .13.9 6 1.39 0.80 2.61 3.3
AC10 8 9.18 2.96 21.27 7.2 6 3.87 3.16 4.70 1.5
DU174 8 7.15 ,0.78 .25 .32 7 1.92 1.13 4.80 4.3
92BR025 7 7.31 1.97 .25 .12.7 6 2.37 ,0.78 7.00 .9.0
92UG024 8 1.90 ,0.78 12.09 .15.5 5 0.78 ,0.78 3.10 .4.0
CM244 8 21.78 13.22 .25 .1.9 6 6.85 1.94 22.03 11.3
aall values of the ICs are expressed as mg/ml. A dash indicates: not possible to calculate.
bNumber of laboratories performing the assay.
cLaboratories involved: 3B, 4A, 5A, 6B, 7, 8, 9, 11, 12.
dLaboratories involved: 1, 2, 4B, 5B, 6A, 10, 13.
doi:10.1371/journal.pone.0004505.t003
Table 4. Inter-Laboratory comparisons with TriMab
a.
TZM-bl Assays
c Other Plasmid Based Assays
d
Virus N lab
b Mean IC50 Min IC50 Max IC50 Fold Range N lab
b Mean IC50 Min IC50 Max IC50 Fold Range
92RW009 1 2.52 2.52 2.52 - 4 19.82 4.42 .25 .5.7
VI 191 3 3.57 2.06 4.81 2.3 3 11.73 9.68 15.3 1.6
SF 162 3 ,0.78 ,0.78 ,0.78 - 4 ,0.78 ,0.78 ,0.78 -
MN(P) 3 ,0.78 ,0.78 ,0.78 - 2 ,0.78 ,0.78 1.00 .1.3
QH0692 3 1.08 0.80 1.45 1.8 3 1.79 1.30 2.61 2.0
AC10 3 3.67 3.16 4.61 1.5 3 4.08 3.44 4.70 1.4
DU174 3 2.81 1.97 4.80 2.4 4 1.44 1.13 1.70 1.5
92BR025 2 1.75 ,0.78 4.34 .5.6 4 2.76 0.91 7.00 7.7
92UG024 2 ,0.78 ,0.78 ,0.78 - 3 0.98 ,0.78 3.10 .4.0
CM244 2 4.48 4.05 4.96 1.2 4 8.47 1.94 22.03 11.3
aall values of the ICs are expressed as mg/ml. A dash indicates: not possible to calculate.
bNumber of laboratories performing the assay.
cLaboratories involved: 2, 5B, 10.
dLaboratories involved: 1, 4B, 6A, 13.
doi:10.1371/journal.pone.0004505.t004
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hierarchy was not maintained.
Detailed comparisons within individual laboratory
methods
Intracellular - p24 assay. The standard IC-p24 assay is
based on PBMC infection, but it can also be adapted to measure
neutralization using other target cells such as immature dendritic
cells (DC) and monocyte-derived macrophages (MDM). Indeed,
neutralizing Mabs had lower ICs on DC and even still lower ICs
on MDM (CD4-T-cells,DC,MDM) [31]. For the three viruses
VI191, SF162 and 92BR025 for which HIV-1 replication in
MDM was sufficient, the Fc-gamma mediated inhibitory assay was
performed. We found a 7.5 to more then 300% increase of IC50
or IC90 for the Mabs when macrophages were used as target cells
instead of PBMC whereas similar IC50s and IC90s were recorded
for sCD4 in the two cell systems (Table 5). These results support
previous data obtained with neutralizing Mabs and sCD4 on the
three other primary isolates BaL, Bx08 and TV1 [31].
Plaque reduction assays on GHOST(3) and U87.CD4
cells. For IC50 comparisons with the other assays the
GHOST(3) cells expressing CCR5 or CXCR4 were used. In
general, results of the plaque reduction assay fit in the middle
range of IC50s of the other VI assays; better for some neutralizing
reagents and viruses, worse for other neutralizing reagents and
viruses (laboratory 9 in Figure 1 and Figure 2). This is in
agreement with the observation that the neutralization sensitivity
of assay types depended on both the virus and neutralizing reagent
and, also with the plaque reduction assay, no general trend could
be seen apart from this.
We also compared the two cell lines, GHOST(3) and U87.CD4,
for assaying HIV-1 neutralization sensitivity. This comparison was
done at one single reagent concentration (5 mg/ml) and showed a
close agreement of the results on the two cell types (Figure 3).
Fusion assay. The fusion assay almost invariably showed the
highest threshold for the detection of neutralization, except for
sCD4. Strikingly, when mouse 3T3 cells were used as target cells
the anti-gp41 Mab 4E10 did not neutralize any of the viruses
(laboratory 3A in Figure 1). Since few viruses were neutralized
with TriMab as well, we considered the possibility that the anti-
gp41 component of TriMab (Mab 2F5) could prevent
neutralization by the other components.
To investigate whether the nature of the target cell was affecting
neutralization, experiments were repeated with the human
epithelial cell line (HeLa) endogenously expressing CXCR4 and
engineered to express human CD4 and CCR5. The individual
components of TriMab were tested separately to see whether anti-
gp41 MAbs inhibited neutralization. The results of parallel
experiments carried out with two viruses, one R5 and one X4
(QH0692 and 92UG024, respectively), showed that the sensitivity
of the fusion assay to detect neutralization was greatly increased
when using HeLa cells as target cells (Table 6). While QH0692
could not be neutralized in 3T3 cells with 25 mg/ml of TriMab, it
was neutralized in HeLa cells with a similar IC50 as in all other
assays. Mab 4E10 neutralized with IC50s comparable to other VI
assays. Interestingly, 2F5, the other Mab directed to gp41,
neutralized as well, as did the other components (2G12 and
IgGb12) of TriMab tested individually. Neutralization of
92UG024 was enhanced on HeLa cells as compared to 3T3 cells
with both TriMab and 4E10. We conclude that the anti-gp41
component of TriMab does not interfere with neutralization in the
fusion assay and that the poor neutralization achieved in initial
experiments was primarily due to the target cell type used in the
assay.
Culture supernatants vs. plasmids in a recombinant virus
assay. An assay based on recombinant viruses produced by co-
infection of HEK-293 cells with a cloned env gp160 gene and an
HIV-1 env vector expressing luciferase allowed the comparison of
plasmid and culture supernatant derived virus populations
(laboratory 4A and and 4B, respectively in Figure 1). All the
DNA-derived and virus-derived env recombinant viruses gave
similar levels of neutralization except for two viruses. The virus-
derived recombinant of 92UG024 was 7-fold more sensitive to
sCD4 than the plasmid derived one. For VI191 the virus-derived
recombinant was between 7- and 74-times more sensitive to
neutralization then the plasmid-derived recombinant by two of the
Mabs and sCD4. Interestingly, the envelope sequences of the two
env-variants, the virus- and plasmid-derived recombinant, of VI191
revealed significant differences at several residues, most notably in
the V3 region. These differences likely contribute to the difference
in sensitivity to neutralization. The envelope sequences from the
other plasmid or culture supernatant derived viruses were
compared and all clustered closely (data not shown).
Discussion
The primary aim of this study was to co-ordinate activities
aimed at comparing methods for the measurement of neutralizing
antibodies to HIV-1 for use in HIV-1 research as well as in human
clinical trials of candidate HIV/AIDS vaccines. The comparisons
led us to the conclusion that at present no single assay can be
recommended for the measurement of HIV-1 neutralization
because the assay results vary significantly depending on both
the virus and the reagent used. Different assays vary in their
sensitivities for measuring of neutralization with the different virus-
reagent combinations. Both the virus and the reagent used for
neutralization influence the assay sensitivity. Since it is not known
at present which in vitro assay best correlates with biological (in vivo)
protection, a panel of neutralization assays has to be recommend-
ed for vaccine evaluation.
In the present study IC50 values were used for the comparisons.
We also considered the use of IC75 or even IC90, but many of the
assays would have been excluded from the comparison as 90% or
even 75% neutralization was often not achieved in most of the
assays used. In conventional VI assays with polyclonal reagents,
such as patient sera or plasma, IC90 values are the parameters
usually considered for measuring neutralization as this increased
stringency parallels increased specificity. In the present study,
Table 5. Comparisons of Intracellular p24 assay performed
with CD4+ T cells and macrophages.
Virus Cells Neutralization (IC90; mg/ml)
477-52D TriMAb 4E10 sCD4
VI191 CD4 T Cells .25 .25 .25 1
Macrophages
1 0.1360.04 0.1360.02 0.0760.02 160
SF162 CD4 T Cells 62.25 5
Macrophages 0.160.1 0.0360.03 0.0860.04 561
92BR025 CD4 T Cells .50 .25 .25 .25
Macrophages .25 10 0.860.4 2864
1Experiments were carried out on macrophages generated from 3 different
donors. Results are the mean+/2standard deviation of two independent
experiments.
doi:10.1371/journal.pone.0004505.t005
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allows comparisons at the level of IC50s. It is important to
emphasize that in future comparisons of the assays with polyclonal
reagents it may be mandatory to compare higher ICs during
evaluation.
Although with some combinations of reagents PSV assays
appeared to be more sensitive for the detection of neutralizing
activity than VI assays, the use of molecularly-cloned pseudo-
viruses has the caveat of testing single clones and not a complex
viral quasispecies as in the case of uncloned viral isolates. Single
clones may give different results and may not be representative of
the prevalent viruses in the quasispecies present in the corre-
sponding isolate, and even less of the virus population circulating
in vivo in the infected individual. This problem might be overcome,
at least in part, by using a pool of amplified clones rather than
single clones, as occurred in the tests performed by partner 4 and
12. One may also consider that the envelope spike density and
stability of pseudoviruses is different from those of primary isolates
and this may account for a higher sensitivity to neutralization.
Continued careful comparison of the assays is therefore very
important.
The use of PBMC as target cells in neutralization assays is the
closest in vitro approximation to the in vivo situation. However,
assays using PBMC from different donors isolated on different
days show great variability in sensitivity as clearly reflected by our
inter-laboratory comparisons. In addition, the number of donors
included in each test, the time of incubation with the virus and the
Table 6. Effect of target cell on neutralization in the fusion
assay.
Virus
Target
cells
a Neutralization (IC50; mg/ml)
TriMab 4E10 2F5 2G12 IgG1 b12
QH0692 3T3 .25 .25 .25 .25 .25
HeLa 4.03 13.38 13.26 6.12 7.18
92UG024 3T3 4.31 24.63 .25 3.86 .25
HeLa 1.44 1.35 3.59 1.25 .25
a3T3, mouse cell line engineered to express CD4 and CCR5 and CXCR4 [51].
HeLa, human cell line engineered to express CD4 and CCR5 [52].
doi:10.1371/journal.pone.0004505.t006
Figure 3. Percentage neutralization with Mabs and sCD4 performed in plaque reduction assay using GHOST(3) or U87.CD4 (CCR5-
or CXCR4-expressing) cells of viruses as indicated. Cut-off is set at 30% neutralization (3 SD above the negative control, based on intra-assay
variation). GHOST(3) cells contain GFP which is activated upon HIV infection and green cells can be counted in a fluorescence microscope 3 days after
infection. The readout in HIV-infected U87.CD4 cultures is light microscopic counting of syncytial cells (single or groups of syncytia) after fixation and
heamatoxylin staining.
doi:10.1371/journal.pone.0004505.g003
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laboratories. Of all the variables, the length of time during which
the inhibitor was present correlated best with the sensitivity of the
assay. Again, however, this relationship seemed to be true for one
virus (SF162), while other viruses did not follow this pattern. These
data reinforce the conviction that there is a great need to
standardize the PBMC assays for HIV-1 neutralization, an activity
that is currently in progress in our network and other groups
worldwide.
An encouraging result emerging from our study was that the
plaque reduction assays gave similar results to the PBMC-based
assays. Using cell lines engineered to express the HIV-1 co-
receptors may provide useful model systems for HIV-1 neutral-
ization. PBMC-produced cytokines and chemokines may add to
the existing variables in a virus-dependent manner, relating to the
sensitivity or resistance of the virus to inhibition by cytokines and/
or chemokines [48]. The use of U87.CD4 or GHOST(3) cells
excludes this variable and provides simple, reliable and cheaper
assay systems. We are currently working on the conversion of the
readout of the plaque reduction assays to an automatic and high-
throughput readout.
Another aspect related to the nature of the target cells used in
HIV-1-neutralization assays has emerged in connection with the
fusion assay. We found that mouse 3T3 cells supported
neutralization by sCD4 but not by Mabs. However, when we
employed human HeLa cells as targets the Mabs acted with similar
efficiency as in other assays. Of note, efficient neutralization by
Mabs was also observed using another human cell line of B-
lymphoid origin, 721–22 (not shown), suggesting that the
sensitivity to Mab-mediated neutralization in the fusion assay
depends on the specific characteristics of the cell lines used as
targets, with human cells showing a greater sensitivity than murine
cells. In contrast to the results obtained in the fusion assay with
murine target cells, Mabs showed an increased inhibitory activity
when macrophages were used as target cells instead of PBMC in
VI assays. The macrophage-based assay detected neutralization
mediated by the Fab as well as the Fcc fragment of the
immunoglobulin. Conceivably, the antibodies induced endocytosis
and degradation of immune complexes via binding to FccR1
receptor (CD64) on macrophages [49]. Moreover, CD64 engage-
ment by immunoglobulins has been reported to trigger a negative
regulatory signal that suppresses HIV-1 replication in macrophag-
es. Whether these additional mechanisms contribute to HIV-1
inhibition in macrophages in vivo need to be investigated. It has
also been described that the level of CCR5 but not CD4
expression on the cell surface determines neutralization by certain
MAbs. For example, neutralization by 4E10 was less effective in
HeLa cells engineered to express CCR5 at high levels as compared
to low levels (comparable to those on CD4+ T lymphocytes) [50].
This question is particularly pertinent since in VI assays we used
both cell lines and PBMC. However, such a relationship could not
be established when comparing the plaque-reduction assays,
performed in U87.CD4-CCR5 or GHOST(3)-CCR5 cells, with
assays based on PBMC. In general, IC50s obtained in the plaque-
reduction assays fitted in the middle of the spectrum of sensitivity
of the other VI assays. Interestingly, IC50s obtained with 4E10
against 92RW009 or VI191 were at the lower end of the scale
when using the cell line-based plaque reduction assay (Figure 1).
The present results provided the necessary starting platform for
designing the future strategies of the NeutNet programme. In the
next step, we plan to assay plasma, sera and purified IgG from
human and animal sources in order to make comparison of the
assays more complete. A reduced virus/clone panel of 8 isolates
will be proposed, and a number of polyclonal human plasma
preparations will be evaluated using different assays optimized
according to the data so far obtained. Taken together, the
comparison of 16 different HIV-1 neutralization assays within the
framework of an international network, NeutNet, comprised of 15
laboratories, led us to the conclusion that at present no single assay
can be recommended for use alone as a potential correlate of
vaccine efficacy. Both the virus and the reagent used for
neutralization (here monoclonal antibodies and sCD4) contribute
to the outcome of assay sensitivity, which in certain combinations
is also influenced by the target cell used. Until we gather more
precise information on which assays may correlate with protective
immunity, a panel of neutralization assays must be recommended
for vaccine evaluation.
Supporting Information
Figure S1 Characteristics of the pseudotyped virus based assays.
Assays are grouped as in Figure 1. Plasmid backbone are all pNL4-
3 derived. 1 Five two-fold serial dilutions were used in the
neutralization assay.
Found at: doi:10.1371/journal.pone.0004505.s001 (2.51 MB TIF)
Table S1 Characteristics of the PBMC based assays Footnote to
Supplementary Table S1: 1 Stimulated prior freezing 2 number of
donors used 3number of cells/ml of medium 4 only in medium of
the neutralization assay 5 incubation time (hr) virus and inhibitory
reagent of the neutralization assay 6 absorption time (hr) virus/
inhibitory reagent mix on the cells before wash step 7 3 washes in
case patient’s sera/plasma are used 8 incubation time before virus
infectivity is measured 9 culture period is 2 days for real-time PCR
and 8 days for p24 antigen
Found at: doi:10.1371/journal.pone.0004505.s002 (0.02 MB
XLS)
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